All News
Count Your Telangiectasias (5.29.2026)
Dr. Jack Cush reviews the news, journal articles and missed quiz questions.
Read Article
Safety of Biologics and Novel Agents
Dr. Jack Cush reviews safety of biologics and novel agents.
Read Article
#OP0340 Long-term DARALUP data suggest CD38-targeting with daratumumab may be promising in refractory SLE, with rapid serologic and clinical improvements sustained to 84 weeks in many patients. Flares occurred in 6/10 patients but responded to belimumab. #EULAR2026 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
Post marketing safety signals of anifrolumab from US FDA adverse event reporting system - herpes zoster significantly associated.
Others include infusion reactions and intermittent hypersensitivity @RheumNow ##EULAR2026 #POS1067
Bella Mehta bella_mehta ( View Tweet)
Interesting poster #POS0939 from @SteZhao #EULAR2026
Long-term or recurrent antibiotic use in childhood associated w doubled risk of axSpA in HLA-B27+ individuals
11,611 HLA-B27+ UK biobank
Recall bias? Yes but self-reported exposure validated with primary care data
@RheumNow https://t.co/VmxI3BW6FE
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2026 OP0335 Open label extension study of Phase II Ianalumab RCT in #SLE: some patients treated with IAN for up to 1 year, had persistent benefits (median 44 wks post-IAN) following Bcell recovery. Important info to judiciously treat while balancing infection risk @RheumNow https://t.co/DEkGMYwy3H
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
103 patients with ICI-induced inflammatory arthritis. 37.9% died during follow-up.
Maximum prednisone dose above 20mg to treat rheumatologic immune-related adverse events was associated with significantly worse overall survival HR 2.35 (95% CI 1.18–4.69, p=0.015). Cumulative https://t.co/vAmIAH7B64
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
True or False: After successfully treating herpes zoster, it is considered safe to restart anti-TNF therapy without a significant risk of recurrence. See if you got it right in this week's RheumIQ quiz at https://t.co/DX0qT1iNF2 https://t.co/pGggdVPhmh
Dr. John Cush RheumNow ( View Tweet)
EGPA https://t.co/zlquehIZQ6
Rheumatology update aabdogafar ( View Tweet)
Veterans Administration study of 301 #RA pts Rx w/ immune checkpoint inhibitor (ICI) for cancer shows all cause mortality in ICI Rx Cancer pts was no worse when RA pts took ICIs (1.09; 0.94–1.25). Cause of death similar; Infx were rare (<1.0%) https://t.co/3ZYujU5nyE https://t.co/MCDcdWHcVx
Dr. John Cush RheumNow ( View Tweet)
VACIMRA RCT in 249 RA pts on MTX were PCV13 vaccinated & continued or held MTX x 4wks. Best humoral responses w/ holding MTX x4wks with no clinical detriment over next 12 mos (remission, LDA, Xray outcomes) https://t.co/b6ByOYY0Fi https://t.co/XeJURKLpL8
Dr. John Cush RheumNow ( View Tweet)
30 yr Retrospective study of 1216 SLE hospitalizations in Barcelona - SLE flares & infections were most frequent. Hosp for infections signif. increased & in last 5yrs, exceeded Dz flares (34% vs. 26%). Younger pts had more flare hosp; older more infx hosp. Over time infx have https://t.co/TkUiXaoL1R
Dr. John Cush RheumNow ( View Tweet)
The safe/right choice is H. Zoster. You never fully eradicate invasive fungal or NTM infections. HBV is too risky to again use TNFi again. After H.zoster is Rx,there is evidence its safe to restart TNFi without risk of recurrence. Vagal N. Stim is the mechanistically same as
Dr. John Cush RheumNow ( View Tweet)
RHEUM Survey: After treating which infection can you safely resume anti-TNF therapy?
Dr. John Cush RheumNow ( View Tweet)
RHEUM Survey: After treating which infection can you safely resume anti-TNF therapy?
Dr. John Cush RheumNow ( View Tweet)
Immune-Mediated Inflammatory Diseases Following Uveitis
A Korean insurance claims data study showed children and adolescents diagnosed with uveitis have a 7-fold increased risk of developing an immune-mediated inflammatory disorder (IMID).
https://t.co/NJI4369ygL https://t.co/6mHK8hYMeG
Dr. John Cush RheumNow ( View Tweet)
Does RTX work in CNS lupus? Japanese experience in 17 refractory NP-SLE pts Rx w/ RTX - 16/17 had significant improve. & 1 partial improvement -- none had NP-SLE relapse. Two died during COVID> https://t.co/GpCgpSxn37 https://t.co/PMz05MHBhj
Dr. John Cush RheumNow ( View Tweet)
Infectious Rheumatology (5.15.2026)
Dr. Jack Cush discusses his favorite journal articles from the past week on RheumNow.
https://t.co/MzqDykG78w https://t.co/z7BsADXo4x
Dr. John Cush RheumNow ( View Tweet)
10yr retrosp. study of 110 Still’s dz pts. MAS occurred in 37% (1/2 @onset; assoc w/ serositis) and ILD observed in 82% (also assoc w/ MAS, polycyclic course) https://t.co/SNa0KiWfgY https://t.co/xbpCuHdJka
Dr. John Cush RheumNow ( View Tweet)
RA adds to mortality risk in nontuberculous mycobact. infx (NTM). Retro study 1420 NTM pts, 66 (4.6) had RA. RA was independent predictor of resp-death (HR 4.30) - partly explained by ILD & systemic inflammation https://t.co/S9bndHsXCE https://t.co/mC74Qve1LZ
Dr. John Cush RheumNow ( View Tweet)
